Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-ATP1A3 antibody [EPR14137] - N-terminal (ab182572)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR14137] to ATP1A3 - N-terminal
  • Suitable for: IP, WB
  • Reacts with: Mouse, Rat, Human

Overview

  • Product name

    Anti-ATP1A3 antibody [EPR14137] - N-terminal
    See all ATP1A3 primary antibodies

  • Description

    Rabbit monoclonal [EPR14137] to ATP1A3 - N-terminal

  • Host species

    Rabbit

  • Tested Applications & Species

    Application Species
    IP
    Human
    WB
    Mouse
    Rat
    Human
    See all applications and species data

  • Immunogen

    Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • WB: Mouse and rat brain lysate. Human fetal brain lysate. Human hippocampus tissue lysate. IP: Human brain lysate.

  • General notes

     This product was previously labelled as alpha 3 Sodium Potassium ATPase

     

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.

    One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.

    Learn more here.

Properties

Images

  • Western blot - Anti-ATP1A3 antibody [EPR14137] - N-terminal (ab182572)
    Western blot - Anti-ATP1A3 antibody [EPR14137] - N-terminal (ab182572)
    All lanes : Anti-ATP1A3 antibody [EPR14137] - N-terminal (ab182572) at 1/5000 dilution

    Lane 1 : Mouse brain lysate
    Lane 2 : Rat brain lysate
    Lane 3 : Human fetal brain lysate
    Lane 4 : Human hippocampus lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

    Predicted band size: 111 kDa



    The 150 KDa band is caused by glycosylation which is consistent with what has been described in PMID: 22797008.

  • Immunoprecipitation - Anti-ATP1A3 antibody [EPR14137] - N-terminal (ab182572)
    Immunoprecipitation - Anti-ATP1A3 antibody [EPR14137] - N-terminal (ab182572)
    ATP1A3 was immunoprecipitated from 0.35 mg human brain lysate 10 ug with ab182572 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab182572 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP)(ab131366) was used at 1/5000 dilution.

    Lane 1: human brain lysate 10 ug

    Lane 2: ab182572 IP in human brain lysate

    Lane 3: Rabbit monoclonal IgG (ab172730) instead of ab182572 in human brain lysate

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.

    Exposure time: 5 seconds

  • Anti-ATP1A3 antibody [EPR14137] - N-terminal (ab182572)
    Anti-ATP1A3 antibody [EPR14137] - N-terminal (ab182572)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Alternative products to Anti-ATP1A3 antibody [EPR14137] - N-terminal (ab182572)

© 2021 Astana Biomed Group LLP. All rights reserved.